financetom
Business
financetom
/
Business
/
Marriott Q3 profit beats expectations as luxury hotels outperform
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Marriott Q3 profit beats expectations as luxury hotels outperform
Nov 4, 2025 4:24 AM

Overview

* Marriott ( MAR ) Q3 adjusted EPS beats analyst expectations

* Company's adjusted net income for Q3 exceeds analyst estimates

* Marriott ( MAR ) repurchased 3 mln shares for $0.8 bln in Q3

Outlook

* Marriott ( MAR ) expects full-year 2025 RevPAR growth of 1.5% to 2.5%

* Company anticipates net rooms growth approaching 5% for 2025

* Marriott ( MAR ) plans to return approx. $4 bln to shareholders in 2025

Result Drivers

* INTERNATIONAL REVPAR - International markets saw a 2.6% increase in RevPAR, driven by strong performance in APEC regions like Japan, Australia, and Vietnam

* LUXURY SEGMENT - Luxury hotels outperformed with a 4% rise in RevPAR due to robust demand and strong rate performance

* ROOMS GROWTH - Co added 17,900 net rooms in Q3, contributing to a 4.7% increase in net rooms from Q3 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $2.47 $2.39

Adjusted (21

EPS Analysts

)

Q3 EPS $2.67

Q3 Beat $674 mln $649.77

Adjusted mln (17

Net Analysts

Income )

Q3 Net $728 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 10 "strong buy" or "buy", 16 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the hotels, motels & cruise lines peer group is "buy."

* Wall Street's median 12-month price target for Marriott International Inc ( MAR ) is $281.00, about 6.1% above its November 3 closing price of $263.89

* The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Greece names Chevron, Helleniq Energy consortium as preferred bidder for offshore gas search
Greece names Chevron, Helleniq Energy consortium as preferred bidder for offshore gas search
Oct 24, 2025
ATHENS (Reuters) -Greece has named a consortium of U.S. oil major Chevron ( CVX ) and Helleniq Energy, the country's biggest oil refiner, as preferred bidder for gas exploration in southern offshore blocks, the Greek energy ministry said on Friday. The move comes after Chevron ( CVX ) and Helleniq submitted a joint bid in a Greek tender this year...
China's Satellite Chemical pauses ethylene project amid US trade tensions, sources say
China's Satellite Chemical pauses ethylene project amid US trade tensions, sources say
Oct 24, 2025
* Satellite Chemical is China's biggest importer of US ethane * Project paused amid trade tensions, lack of government and regulatory approvals * Ethane cracker is part of multibillion-dollar expansion plan By Trixie Yap and Chen Aizhu SINGAPORE, Oct 24 (Reuters) - Satellite Chemical , China's largest importer of U.S. ethane, has paused plans to build its third ethylene unit...
Sanofi profits beat forecasts despite 'negative buzz' around vaccines
Sanofi profits beat forecasts despite 'negative buzz' around vaccines
Oct 24, 2025
By Bhanvi Satija LONDON, Oct 24 (Reuters) - Sanofi on Friday reported third-quarter profit that beat forecasts, boosted by demand for blockbuster asthma drug Dupixent, but the French company flagged lower vaccination rates partly due to a negative buzz around vaccines. Sanofi's sales of its flu and COVID vaccines dropped 16.8%, hit by pricing pressure in Germany and lower vaccination...
Orchid Island Capital Q3 Net Income Increases
Orchid Island Capital Q3 Net Income Increases
Oct 24, 2025
03:29 AM EDT, 10/24/2025 (MT Newswires) -- Orchid Island Capital ( ORC ) reported Q3 net income Thursday of $0.53 per diluted share, up from $0.24 a year earlier. Two analysts polled by FactSet expected $0.22. Net interest income for the quarter ended Sept. 30 was $26.9 million, up from $340,000 a year earlier. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved